Achieve Life Sciences Inc (ACHV) - Total Assets
Based on the latest financial reports, Achieve Life Sciences Inc (ACHV) holds total assets worth $33.10 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check ACHV total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Achieve Life Sciences Inc - Total Assets Trend (1994–2025)
This chart illustrates how Achieve Life Sciences Inc's total assets have evolved over time, based on quarterly financial data. Check ACHV operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Achieve Life Sciences Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Achieve Life Sciences Inc's total assets of $33.10 Million consist of 95.5% current assets and 4.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 50.1% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $751.00K | 1.8% |
| Goodwill | $1.03 Million | 2.5% |
Asset Composition Trend (1994–2025)
This chart illustrates how Achieve Life Sciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see ACHV company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Achieve Life Sciences Inc's current assets represent 95.5% of total assets in 2025, an increase from 59.4% in 1994.
- Cash Position: Cash and equivalents constituted 50.1% of total assets in 2025, up from 0.0% in 1994.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 0.0% in 1994.
- Asset Diversification: The largest asset category is goodwill at 2.5% of total assets.
Achieve Life Sciences Inc Competitors by Total Assets
Key competitors of Achieve Life Sciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SHG:603392
|
China | CN¥13.76 Billion |
|
Amicus Therapeutics Inc
NASDAQ:FOLD
|
USA | $949.87 Million |
|
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294
|
China | CN¥8.41 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥772.57 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Yantai Zhenghai Bio-Tech Co Ltd
SHE:300653
|
China | CN¥964.85 Million |
|
Jiangsu GDK Biotechnology Co Ltd
SHG:688670
|
China | CN¥1.48 Billion |
Achieve Life Sciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.62 | 3.51 | 9.09 |
| Quick Ratio | 2.62 | 3.51 | 9.09 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $19.23 Million | $17.87 Million | $37.76 Million |
Achieve Life Sciences Inc - Advanced Valuation Insights
This section examines the relationship between Achieve Life Sciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 49.22 |
| Latest Market Cap to Assets Ratio | 12.53 |
| Asset Growth Rate (YoY) | 8.2% |
| Total Assets | $41.79 Million |
| Market Capitalization | $523.56 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Achieve Life Sciences Inc's assets at a significant premium (12.53x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: Achieve Life Sciences Inc's assets grew by 8.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Achieve Life Sciences Inc (1994–2025)
The table below shows the annual total assets of Achieve Life Sciences Inc from 1994 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $41.79 Million | +8.17% |
| 2024-12-31 | $38.63 Million | +99.44% |
| 2023-12-31 | $19.37 Million | -35.37% |
| 2022-12-31 | $29.97 Million | -36.92% |
| 2021-12-31 | $47.52 Million | +17.91% |
| 2020-12-31 | $40.30 Million | +91.19% |
| 2019-12-31 | $21.08 Million | +10.45% |
| 2018-12-31 | $19.08 Million | +92.92% |
| 2017-12-31 | $9.89 Million | -63.99% |
| 2016-12-31 | $27.47 Million | -52.81% |
| 2015-12-31 | $58.21 Million | +3.41% |
| 2014-12-31 | $56.29 Million | +1.08% |
| 2013-12-31 | $55.69 Million | -32.10% |
| 2012-12-31 | $82.02 Million | +20.59% |
| 2011-12-31 | $68.02 Million | -24.36% |
| 2010-12-31 | $89.92 Million | +30.35% |
| 2009-12-31 | $68.98 Million | +366.40% |
| 2008-12-31 | $14.79 Million | -67.31% |
| 2007-12-31 | $45.25 Million | -33.94% |
| 2006-12-31 | $68.49 Million | +18.27% |
| 2005-12-31 | $57.91 Million | +156.59% |
| 2004-12-31 | $22.57 Million | +5.13% |
| 2003-12-31 | $21.47 Million | +19.70% |
| 2002-12-31 | $17.93 Million | +13.05% |
| 2001-12-31 | $15.86 Million | +10.86% |
| 2000-12-31 | $14.31 Million | -20.94% |
| 1999-12-31 | $18.10 Million | -3.72% |
| 1998-12-31 | $18.80 Million | -34.95% |
| 1997-12-31 | $28.90 Million | +7.84% |
| 1996-12-31 | $26.80 Million | +36.73% |
| 1995-12-31 | $19.60 Million | +512.50% |
| 1994-12-31 | $3.20 Million | -- |
About Achieve Life Sciences Inc
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreement… Read more